← Back to Search

Yoga for Peripheral Neuropathy

N/A
Recruiting
Led By Ting Bao, MD, DABMA, MS
Research Sponsored by Dana-Farber Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Self-reported moderate to severe CIPN pain, as defined by a score of 4 or greater on the BPI-SF average pain item over the past week
Willing to adhere to requirement that no new pain medication be taken throughout the first 12 weeks of the study period
Must not have
Patients who have received physical therapy or practiced yoga for CIPN in the past 3 months. As patients who have received physical therapy or practiced yoga in this time period may already be experiencing the benefits of yoga/stretching therapy, we will exclude such patients.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 24 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing if yoga can help reduce nerve pain caused by cancer treatment. It will compare yoga classes, educational sessions about nerve pain and yoga, and typical care. The study aims to see if yoga can improve balance, reduce falls, and enhance quality of life for patients with chemotherapy-induced nerve pain. Yoga has been shown to improve cancer-related fatigue and sleep quality in breast cancer patients during and following treatment.

Who is the study for?
This trial is for English-speaking adults over 18 who finished chemotherapy like platinum agents or taxanes at least three months ago and have nerve pain from it (CIPN). They should not have changed their pain meds in the last three months, can't start new ones during the study, and haven't done yoga or physical therapy for CIPN recently.
What is being tested?
The study tests if yoga can help with nerve pain caused by chemo. Participants will either take yoga classes, attend educational sessions about CIPN and therapies, or receive usual care with standard medications. The effects on balance, fall risk, quality of life, and touch sensitivity are compared.
What are the potential side effects?
Yoga is generally safe but may include muscle soreness or strain. Usual care side effects depend on the specific medications used for CIPN treatment which can vary among individuals.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have moderate to severe nerve pain from chemotherapy, scoring 4 or more on a pain scale.
Select...
I agree not to start any new pain medications for the first 12 weeks of the study.
Select...
I have been diagnosed with chemotherapy-induced peripheral neuropathy.
Select...
My cancer is stable or I am cancer-free according to my last check-up.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have not done physical therapy or yoga for CIPN in the last 3 months.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 24 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 24 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
measuring Chemotherapy-Induced Peripheral Neuropathy pain severity after Yoga

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: YogaExperimental Treatment1 Intervention
Participants will receive twice weekly yoga over the course of 8 weeks.
Group II: Education control (EC)Experimental Treatment1 Intervention
Participants will receive twice weekly education over the course of 8 weeks
Group III: Usual care (UC)Active Control1 Intervention
8 weeks of usual care

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Peripheral neuropathy treatments aim to alleviate symptoms and improve quality of life. Common treatments include medications like gabapentin and tricyclic antidepressants, which work by modulating nerve signals to reduce pain. Exercise therapies, such as yoga, improve physical function, reduce pain, and enhance overall well-being by increasing blood flow, reducing inflammation, and promoting nerve health. These treatments are crucial as they address both the physical and psychological aspects of neuropathy, helping patients manage pain and improve their daily functioning.

Find a Location

Who is running the clinical trial?

Dana-Farber Cancer InstituteLead Sponsor
1,113 Previous Clinical Trials
358,613 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,957 Previous Clinical Trials
41,111,819 Total Patients Enrolled
14 Trials studying Peripheral Neuropathy
1,473 Patients Enrolled for Peripheral Neuropathy
Memorial Sloan Kettering Cancer CenterLead Sponsor
1,979 Previous Clinical Trials
599,570 Total Patients Enrolled
3 Trials studying Peripheral Neuropathy
154 Patients Enrolled for Peripheral Neuropathy
Ting Bao, MD, DABMA, MSPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
3 Previous Clinical Trials
353 Total Patients Enrolled
2 Trials studying Peripheral Neuropathy
103 Patients Enrolled for Peripheral Neuropathy
Ting Bao, MDPrincipal InvestigatorDana-Farber Cancer Institute
5 Previous Clinical Trials
514 Total Patients Enrolled
1 Trials studying Peripheral Neuropathy
51 Patients Enrolled for Peripheral Neuropathy
Jun Mao, MD, MSCEPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
10 Previous Clinical Trials
2,002 Total Patients Enrolled

Media Library

Yoga Clinical Trial Eligibility Overview. Trial Name: NCT05121558 — N/A
Peripheral Neuropathy Research Study Groups: Education control (EC), Yoga, Usual care (UC)
Peripheral Neuropathy Clinical Trial 2023: Yoga Highlights & Side Effects. Trial Name: NCT05121558 — N/A
Yoga 2023 Treatment Timeline for Medical Study. Trial Name: NCT05121558 — N/A
~51 spots leftby Oct 2025